Overall survival of patients with metastatic colorectal cancer who completed 16 weeks of first-line chemotherapy treatment was unaffected by oral maintenance of capecitabine compared with no treatment, according to data from phase 3 trial presented at ASCO21.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
